Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PDXK | O00764 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28467294 | 0.98 | PDE10A (0.38) | PDE10APDXKPDK2 | |
| SCHEMBL28988161 | 0.77 | ALDH1A1 (0.40) | PDXK | |
| SCHEMBL30326075 | 0.77 | ALDH1A1 (0.40) | PDXK | |
| SCHEMBL22074101 | 0.77 | PDXK (0.31) | PDXK | |
| SCHEMBL5435005 | 0.77 | RXFP1 (0.39) | PDXKLMNA | |
| SCHEMBL16476949 | 0.77 | PDE10A (0.35) | PDE10A | |
| SCHEMBL29953076 | 0.76 | MEN1 (0.36) | PDK2LMNA | |
| SCHEMBL11154637 | 0.71 | PDXK (0.36) | PDE10APDXK | |
| SCHEMBL19308504 | 0.71 | PDE10A (0.32) | PDE10APDXK | |
| SCHEMBL18597002 | 0.70 | PDE10A (0.31) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907514-A | Multifunctional fiber and preparation method and application thereof | 北京洁尔爽高科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-108950645-B | Aluminum and aluminum alloy anodic oxidation nickel-free sealing agent | 上海铝通化学科技有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| CN-108950645-A | A kind of aluminium and aluminium alloy anode oxide are without nickel sealer | 上海铝通化学科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-8168766-B2 | Process of making 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides and intermediates therefor | ScnioPharm Taiwan Ltd. (TW) | 2012-05-01 | — | — | US | disclosed |
| US-20100056771-A1 | Process of Making 2-Deoxy-2,2-Difluoro-D-Ribofuranosyl Nucleosides and Intermediates Therefor | SCINOPHARM TAIWAN LTD. (TW) | 2010-03-04 | — | — | US | disclosed |
| US-7572898-B2 | Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonate and use thereof for making a beta nucleoside | SCINOPHARM TAIWAN, LTD. (TW) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | FGFR1, FGFR2, FGFR3 | PDE10A 3668/4885PDXK 113/4885PDK2 262/4885 |
| US-20100056771-A1 | Process of Making 2-Deoxy-2,2-Difluoro-D-Ribofuranosyl Nucleosides and Intermediates Therefor | SAMHD1, DPYD, GARS1 | PDE10A 4478/4885PDXK 2980/4885PDK2 1024/4885 |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | FGFR1, FGFR2, FGFR3 | PDE10A 3668/4885PDXK 113/4885PDK2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.